Nonalcoholic Steatohepatitis (NASH) Market Report to 2027

Friday, December 8, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, December 8, 2017 /PRNewswire/ --

Forecasts and Analysis by Therapeutics (GFT 505,

Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E, Pioglitazone, Placebo) and Region

• Do you need definitive NASH market data? • Succinct NASH market analysis? • Technological insight? • Actionable business

recommendations?

Read on to discover how this definitive report can transform your own research and save you time.  

The increase in prevalence of hepatic pathology and its pathophysiology have propelled the growth of the novel therapeutic studies, which has given birth to the novel therapeutic solutions such as Farnesoid X Receptor (FXR) agonists, incretins and probiotics. Most of these studies are in last phase of their clinical trials and commercialization is expected within a short period of time that could be used in treating patients with NASH.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

Report highlights 

• 132 quantitative tables, charts, and graphs across 145 pages 

• Global NASH market outlook and analysis from to 2027 

• Global NASH submarket forecasts and analysis from to 2027 • GFT 505 • Obeticholic Acid (INT-747) • Simtuzumab and Liraglutide (Victoza) • Vitamin E • Pioglitazone • Placebo

• Regional and National NASH market forecasts to 2027 • North America forecast to 2027: • US forecast to 2027 • Canada forecast to 2027 • Mexico forecast to 2027

• South America forecast to 2027: • Brazil forecast to 2027 • Argentina forecast to 2027 • Paraguay forecast to 2027 • Bolivia forecast to 2027 • Rest of South America forecast to 2027

• Europe forecast to 2027: • Germany forecast to 2027 • UK forecast to 2027 • France forecast to 2027 • Italy forecast to 2027 • Spain forecast to 2027 • Rest of Europe forecast to 2027

• Asia-Pacific forecast to 2027 • Japan forecast to 2027 • India forecast to 2027 • China forecast to 2027 • Australia forecast to 2027 • Thailand forecast to 2027 • Rest of Asia-Pacific forecast to 2027

• Rest of World forecast to 2027: • Middle East forecast to 2027 • Africa forecast to 2027 • Other Countries forecast to 2027

Key questions answered • What does the future hold for the Pharmaceutical industry with regards to Nonalcoholic Steatohepatitis (NASH) • Where should you target your business strategy? • Which applications should you focus upon? • Which disruptive technologies should you invest in? • Which companies should you form strategic alliances with? • Which company is likely to success and why? • What business models should you adopt? • What industry trends should you be aware of?

Target audience • Leading Pharmaceutical companies • Suppliers • Contractors • Technologists • R&D staff • Consultants • Analysts • CEO's • CIO's • COO's • Business development managers • Investors • Governments • Agencies • Banks

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com (+44-(0)-20-7336-6100) or refer to our website: https://www.visiongain.com/Report/2071/Nonalcoholic-Steatohepatitis-(NASH)-Market-Report-to-2027

Companies Mentioned in the Report 

Abbott Laboratories

AbbVie, Inc.

Alkermes Plc

Amarin Corp. Plc

Amgen, Inc.

Amnis Corporation

Array BioPharma, Inc.

Associates Of Cape Cod  Inc.

Astex Pharmaceuticals  Inc.

AstraZeneca Plc

ASYMPTOTE LTD

Bayer AG

Bayer Corporation

Bayer HealthCare AG

Bayer Schering Pharma Aktiengesellschaft

BioLife Solutions, Inc.

BioMarin Pharmaceutical, Inc.

Biotest AG

Bristol-Myers Squibb Co.

Cardax, Inc.

Cardinal Health, Inc.

Ceapro, Inc.

Celgene Corp.

Cephalon, Inc.

Chugai Pharmaceutical Co., Ltd.

CK Life Sciences International (Holdings), Inc.

Consensys Imaging Service  Inc.

Cornerstone Research & Development  Inc.

Crescendo Bioscience, Inc.

CTI BioPharma Corp.

Deroyal Industries  Inc.

Domain Therapeutics SA

Emd Millipore Corporation

Emd Serono  Inc.

Endo International Plc

Evotec AG

Galderma Sa

Galmed Pharmaceuticals Ltd.

GE HEALTHCARE LTD

Genfit SA

Gilead Sciences, Inc.

Henry Schein, Inc.

Illumina, Inc.

Immuron Limited

Intercept Pharmaceuticals, Inc.

Janssen Biotech, Inc.

JHL Biotech, Inc.

Johnson & Johnson

Laboratoire Theramex

Laboratory Corp. of America Holdings

LifeWatch AG

Lombard Medical, Inc.

Lonza Group AG

McKesson Corp.

Medline Industries  Inc.

Medtronic Plc

Merck & Co., Inc.

Merck KGaA

MorphoSys AG

Motion Picture And Television Fund

Myrexis, Inc.

Myriad Genetics, Inc.

National Cancer Institute

NBTY, Inc.

Nexvet Biopharma PLC

Northwell Health  Inc.

Novartis AG

Novartis AG

Novo Nordisk AG

Opexa Therapeutics, Inc.

Otsuka Pharmaceutical Co.  Ltd.

Owens & Minor, Inc.

Panacos Pharmaceuticals, Inc.

PELICAN HEALTHCARE LTD

Pfizer Inc.

Polymer Technology Systems  Inc.

Progyny Inc.

Quanterix Corp.

Quest Diagnostics, Inc.

Smith & Nephew Plc

Vertex Pharmaceuticals, Inc.

Windtree Therapeutics, Inc.

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store